Peer-reviewed veterinary case report
Aliskiren reduces atrial changes in dogs with atrial fibrillation
By Satoh, Akira et al.·Published in Heart and vessels·2017·Department of Cardiovascular Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation.
- Species:
- dog
Plain-English summary
A group of dogs with atrial fibrillation (AF) were treated with a medication called aliskiren to see if it could help their heart condition. The dogs that received aliskiren showed less electrical and structural changes in their hearts compared to those that did not receive the medication. Specifically, aliskiren helped reduce heart enlargement and tissue scarring, which are common issues in dogs with AF. This suggests that aliskiren may be a beneficial treatment option for managing atrial fibrillation in dogs.
People also search for: dog atrial fibrillation treatment · aliskiren for dogs heart problems · canine heart disease medication
Abstract
Aliskiren, a direct renin inhibitor is expected to achieve sufficient suppression of renin-angiotensin system. We evaluated the effect of aliskiren on the electrical and structural remodeling in a canine atrial fibrillation (AF) model. Twenty-eight dogs were divided into three groups: (1) pacing control group (n = 12), with continuous atrial rapid pacing for 3 or 6 weeks, (2) pacing + aliskiren group (n = 12), with oral aliskiren (30 mg/kg/day), and (3) sham group (n = 4), no pacing nor drug administration. Electrophysiological properties and AF inducibility were evaluated every week. After the protocol, the left atrial tissue was sampled for the further histological and mRNA analysis. The electrical remodeling, AF inducibility, the left atrial enlargement and interstitial fibrosis were observed in pacing control group and were more prominent in the 6-week protocol (vs. 3 week, p < 0.05). The mRNA expressions of matricellular proteins exhibited upregulation in 3-week pacing control, but these upregulations became insignificant in 6 weeks. In contrast, collagen type 3 exhibited significant upregulation in 6 week but not in 3-week protocol. These changes were suppressed in the pacing + aliskiren group. Aliskiren suppressed the atrial remodeling in a canine AF model. This effect was accompanied by the suppression of tissue fibrosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27401739/